Research record: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Published in J Clin Oncol; first publication date 2026-05-21. PMID 42166704.
This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.